POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Potassium is the major intracellular cation necessary for nerve conduction, muscle contraction, and acid-base balance. Chloride is the major extracellular anion and helps maintain osmotic pressure and acid-base balance. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.

What the body does with it

Metabolism	Potassium is excreted primarily by the kidneys; metabolism not applicable as it is an electrolyte.
Excretion	Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion. Fecal: <10% (minor route). Biliary: negligible.
Half-life	Potassium has a functional half-life of approximately 2-4 hours for distribution, but terminal elimination is not defined due to rapid renal excretion and homeostatic regulation. In states of normal renal function, excess potassium is cleared within hours.
Protein binding	Potassium is not bound to plasma proteins (<1%).
Volume of Distribution	Approximately 0.5-0.6 L/kg, reflecting distribution primarily in extracellular fluid (ECF). Total body potassium is ~50 mEq/kg, but Vd for administered potassium is largely limited to ECF until intracellular uptake occurs.
Bioavailability	Intravenous: 100% (only route for this formulation). No oral bioavailability as this is an IV solution.
Onset of Action	Intravenous: Onset is immediate upon infusion; clinical effect on serum potassium occurs within minutes. No other routes for this formulation.
Duration of Action	Intravenous infusion: Duration is limited to the infusion period and short-lived after cessation; redistribution and excretion begin immediately. Continuous infusion required for sustained effect. Does not provide prolonged duration.

Classification & Brands

Dosing & administration

Intravenous infusion, typical dose is 10 mEq/hour (as potassium chloride 0.3% in sodium chloride 0.9%) at a rate not exceeding 10 mEq/hour for maintenance; maximum 20 mEq/hour in severe deficiency with cardiac monitoring.

Dosage form	INJECTABLE
Renal impairment	Avoid use if GFR < 30 mL/min/1.73 m² due to risk of hyperkalemia. For GFR 30-50 mL/min/1.73 m², reduce dose by 50% and monitor serum potassium frequently.
Liver impairment	No specific dose adjustment for Child-Pugh A or B; for Child-Pugh C (severe hepatic impairment), consider potassium-sparing agents and reduce dose by 50% due to increased risk of hyperkalemia.
Pediatric use	Intravenous infusion: 0.5-1 mEq/kg/dose (max 1 mEq/kg) infused over 1-2 hours, not to exceed 0.5 mEq/kg/hour; monitor serum potassium and ECG.
Geriatric use	Initiate at lower end of adult dosing (e.g., 5 mEq/hour) with careful monitoring of serum potassium and renal function due to age-related decreased GFR and risk of hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium and sodium are normal constituents of breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio not applicable as these are endogenous ions. Compatible with breastfeeding.
Teratogenic Risk	Potassium chloride and sodium chloride are normal body constituents. No teratogenic effects are expected when used appropriately. In all trimesters, there is no known risk of fetal harm from physiologic doses. Overdose or hyperkalemia/hypernatremia may cause maternal complications with secondary fetal effects.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal failure with oliguria or anuria","Addison's disease","Acute dehydration","Concomitant use of potassium-sparing diuretics","In patients with crush injuries, hemolytic reactions, or extensive tissue breakdown"]

Clinical Precautions

Precautions

["Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Monitor serum potassium levels during therapy","Avoid rapid infusion to prevent hyperkalemia and cardiac arrest","Do not administer in concentrated solutions via peripheral vein"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

What the body does with it

Metabolism	Potassium is excreted primarily by the kidneys; metabolism not applicable as it is an electrolyte.
Excretion	Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion. Fecal: <10% (minor route). Biliary: negligible.
Half-life	Potassium has a functional half-life of approximately 2-4 hours for distribution, but terminal elimination is not defined due to rapid renal excretion and homeostatic regulation. In states of normal renal function, excess potassium is cleared within hours.
Protein binding	Potassium is not bound to plasma proteins (<1%).
Volume of Distribution	Approximately 0.5-0.6 L/kg, reflecting distribution primarily in extracellular fluid (ECF). Total body potassium is ~50 mEq/kg, but Vd for administered potassium is largely limited to ECF until intracellular uptake occurs.
Bioavailability	Intravenous: 100% (only route for this formulation). No oral bioavailability as this is an IV solution.
Onset of Action	Intravenous: Onset is immediate upon infusion; clinical effect on serum potassium occurs within minutes. No other routes for this formulation.
Duration of Action	Intravenous infusion: Duration is limited to the infusion period and short-lived after cessation; redistribution and excretion begin immediately. Continuous infusion required for sustained effect. Does not provide prolonged duration.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	Avoid use if GFR < 30 mL/min/1.73 m² due to risk of hyperkalemia. For GFR 30-50 mL/min/1.73 m², reduce dose by 50% and monitor serum potassium frequently.
Liver impairment	No specific dose adjustment for Child-Pugh A or B; for Child-Pugh C (severe hepatic impairment), consider potassium-sparing agents and reduce dose by 50% due to increased risk of hyperkalemia.
Pediatric use	Intravenous infusion: 0.5-1 mEq/kg/dose (max 1 mEq/kg) infused over 1-2 hours, not to exceed 0.5 mEq/kg/hour; monitor serum potassium and ECG.
Geriatric use	Initiate at lower end of adult dosing (e.g., 5 mEq/hour) with careful monitoring of serum potassium and renal function due to age-related decreased GFR and risk of hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium and sodium are normal constituents of breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio not applicable as these are endogenous ions. Compatible with breastfeeding.
Teratogenic Risk	Potassium chloride and sodium chloride are normal body constituents. No teratogenic effects are expected when used appropriately. In all trimesters, there is no known risk of fetal harm from physiologic doses. Overdose or hyperkalemia/hypernatremia may cause maternal complications with secondary fetal effects.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	fluid replacement
Serious Effects